Factores asociados a respuesta virológica en mujeres que usaron profilaxis antirretroviral de gran actividad para transmisión materno-fetal del virus de la inmunodeficiencia humana tipo 1

Nenhuma Miniatura disponível
Data
2008-08-01
Autores
Palacios, Ricardo [UNIFESP]
Senise, Jorge Figueiredo [UNIFESP]
Vaz, Maria José Rodrigues [UNIFESP]
Castelo Filho, Adauto [UNIFESP]
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
INTRODUCTION. Pregnancy is the only circumstance in HIV infection requiring urgent virological response to the antiviral approach because of the influence of plasma viral load (VL) on mother-to-child transmission (MCT) of the disease. This study analyzes factors related to the time needed to reach VL < 400 copies/mL during antiretroviral prophylaxis for MCT.METHODS. The study included a cohort of HIV-1 infected pregnant women enrolled between 2000 and 2005 with baseline CD4+ lymphocyte count > 300 cells/mu L, highly-active antiretroviral prophylaxis for at least 4 weeks, antiretroviral interruption after delivery, and available laboratory data.RESULTS. Seventy-five pregnancies were analyzed. Median baseline VL was 3.71 log(10) copies/mL and CD4+ count was 573 cells/mu L. Prophylaxis started after 26.6 weeks of gestation and lasted up to 11.7 weeks in 75% of cases. The prophylactic regimen was changed in 12 pregnancies, 7 because of toxicity. A protease inhibitor was included in 33 prophylactic regimens, 11 of them with lopinavir. Prophylaxis resulted in undetectable HIV-1 VL within 6.7 weeks in 75% of pregnancies. VL was detectable at the end of prophylaxis in 5 cases. Time to undetectable VL was shorter if baseline VL was less than 100,000 copies/mL and the antiretroviral regimen was not changed during prophylaxis.CONCLUSIONS. To achieve VL < 400 copies/mL at delivery, antiretroviral prophylaxis should be started before 26 to 28 weeks of pregnancy. A potent and well-tolerated prophylactic antiretroviral regimen will likely reduce the time to virological response. Trials investigating alternative regimens (e.g., lopinavir-containing) for patients with late diagnosis during prenatal care or VL >100,000 copies/mL are warranted.
Descrição
Citação
Enfermedades Infecciosas Y Microbiologia Clinica. Barcelona: Ediciones Doyma S A, v. 26, n. 7, p. 411-415, 2008.
Coleções